| 00:00:00 | Welcome |
| 00:03:01 | Contents |
| 00:04:00 | NanoSight Instruments Provide: |
| 00:05:48 | Principle of measurement |
| 00:05:51 | Direct Visualization of Nanoparticles in Suspension |
| 00:05:51 | Optical Arrangement for NanoSight Instruments |
| 00:08:06 | Principle of Measurement |
| 00:08:06 | NTA Sizing is an Absolute Method |
| 00:09:10 | Nanoparticle Tracking Analysis |
| 00:10:10 | Particle Sizing in Action- Software Analysis |
| 00:10:10 | NTA Detection Limits |
| 00:12:19 | Examples |
| 00:12:26 | Example 1: Purified Influenza Virus |
| 00:12:26 | Example 2: Harvest Influenza – Prior to Purification |
| 00:12:26 | Example 3: Adeno Virus (Purified) |
| 00:12:26 | Example 4: Virus Like Particles |
| 00:12:26 | Example 5 – Protein Aggregation |
| 00:12:26 | Example 6- Protein Aggregation at 50 Degrees Celsius |
| 00:12:57 | Example 7: Bacterial Contamination |
| 00:12:57 | Types of Virus |
| 00:13:13 | Types of Virus |
| 00:13:50 | Virus Types Detectable with NanoSight |
| 00:14:28 | Virus Types Currently Below Detection Limit |
| 00:14:59 | ADDITIONAL PARAMETERS OF Nta analyses |
| 00:15:04 | True Size Distribution Profile |
| 00:15:04 | True Size Distribution Profile |
| 00:15:26 | Measurement of Viral Titer |
| 00:16:20 | Particles are Counted |
| 00:16:20 | Resolving Mixtures Through Scatter Intensity |
| 00:18:33 | Fluorescent Mode Available |
| 00:19:36 | Analysis in Complex Biological Media |
| 00:19:36 | Analysis in Complex Biological Media- Fluorescent Mode |
| 00:19:36 | Comparative Technologies |
| 00:19:43 | Plaque Assays |
| 00:20:30 | Correlation: NanoSight, plaque assay, qPCR |
| 00:21:10 | Electron Microscopy |
| 00:21:35 | Flow Cytometric Techniques |
| 00:22:20 | NTA is Proven on a Wide Range of Nanoparticles |
| 00:22:56 | Parameters Measured-Simultaneously, 'Real Time', Particle by Particle |
| 00:23:28 | Nanosight- NTA Devices Worldwide Mapping |
| 00:24:06 | Questions and Answers |
| 00:45:37 | Contact Information |
During this webinar, we introduce the Nanoparticle Tracking Analysis (NTA) technique and discuss how it can provide a range of useful characterization information for virus, vaccine and virus-like particle (VLP) applications. More than a simple particle size analysis, the combination of particle concentration measurements and the fluorescence mode option can provide new insights into your samples. The number-based particle concentration can replace plaque assays for process control of virus concentration and gives direct feedback on VLP formation. Subunit vaccines and other protein based therapeutics can be closely monitored for aggregation, both the typical polydisperse size distributions and quantification of aggregates.